An Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients

Germline genetics, gender and hormonal-signaling pathways are all well described modifiers of cancer risk and progression. Although an improved understanding of how germline genetic variants interact with other cancer risk factors may allow better prevention and treatment of human cancer, measuring and quantifying these interactions is challenging. In other areas of research, Information Theory has been used to quantitatively describe similar multivariate interactions. We implemented a novel information-theoretic analysis to measure the joint effect of a high frequency germline genetic variant of the p53 tumor suppressor pathway (MDM2 SNP309 T/G) and gender on clinical cancer phenotypes. This analysis quantitatively describes synergistic interactions among gender, the MDM2 SNP309 locus, and the age of onset of tumorigenesis in p53 mutation carriers. These results offer a molecular and genetic basis for the observed sexual dimorphism of cancer risk in p53 mutation carriers and a model is proposed that suggests a novel cancer prevention strategy for p53 mutation carriers.

[1]  R. Dahiya,et al.  MDM2 SNP309 Polymorphism as Risk Factor for Susceptibility and Poor Prognosis in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[2]  Gustavo Stolovitzky,et al.  A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. , 2007, Cancer research.

[3]  A. Levine,et al.  A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans , 2007, Oncogene.

[4]  D. Malkin,et al.  Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. , 2007, Cancer research.

[5]  L. J. Veer,et al.  The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes , 2007, European Journal of Human Genetics.

[6]  S. Saigal,et al.  Relative performance of mutual information estimation methods for quantifying the dependence among short and noisy data. , 2007, Physical review. E, Statistical, nonlinear, and soft matter physics.

[7]  S. Zienolddiny,et al.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.

[8]  A. Levine,et al.  MDM2 SNP309 accelerates colorectal tumour formation in women , 2006, Journal of Medical Genetics.

[9]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[10]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[11]  C. Bonaïti‐pellié,et al.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.

[12]  W. Tan,et al.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. , 2005, Cancer research.

[13]  L. Aaltonen,et al.  The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck , 2005, Journal of Medical Genetics.

[14]  A. Levine,et al.  A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells* , 2005, Journal of Biological Chemistry.

[15]  A. Levine,et al.  A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. , 2005, Cancer research.

[16]  William Bialek,et al.  Estimating mutual information and multi-information in large networks , 2005, ArXiv.

[17]  A. Levine,et al.  MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.

[18]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[19]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[20]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[21]  D. Tregouet,et al.  Automated detection of informative combined effects in genetic association studies of complex traits. , 2003, Genome research.

[22]  D. Lane,et al.  Improving cancer therapy by non-genotoxic activation of p53. , 2003, European journal of cancer.

[23]  Shih-Jen Hwang,et al.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. , 2003, American journal of human genetics.

[24]  J. Nicolas,et al.  A new recombinant cell bioassay for ultrasensitive determination of serum estrogenic bioactivity in children. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  D. Clayton,et al.  A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. , 2002, American journal of human genetics.

[26]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[27]  C. Sing,et al.  A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. , 2001, Genome research.

[28]  Jurg Ott,et al.  20 Applications of neural networks for gene finding , 2001 .

[29]  M. Province,et al.  19 Classification methods for confronting heterogeneity , 2001 .

[30]  J. Ott,et al.  Applications of neural networks for gene finding. , 2001, Advances in genetics.

[31]  M. Province,et al.  Classification methods for confronting heterogeneity. , 2001, Advances in genetics.

[32]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[33]  William Bialek,et al.  Synergy in a Neural Code , 2000, Neural Computation.

[34]  C. Bonaïti‐pellié,et al.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals , 2000, British Journal of Cancer.

[35]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[36]  Naftali Tishby,et al.  Synergy and Redundancy among Brain Cells of Behaving Monkeys , 1998, NIPS.

[37]  J. Baron,et al.  Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. , 1994, The Journal of clinical investigation.

[38]  S. Friend,et al.  Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. , 1992, Journal of the National Cancer Institute.

[39]  S. Friend,et al.  Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.